Clinical Trial Update: Bioequivalence Study of Cephalexin Suspension 125 [Phase 1]

View source ↗

Summary

GlaxoSmithKline completed a Phase 1 bioequivalence study of Cephalexin suspension 125 mg.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Tract Infection

Drugs mentioned

• Cephalexin suspension 125 (Cephalexin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Respiratory Tract | Phase 1 | Status: COMPLETED